Gilead Sciences (GILD) reported $6.67 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.3%. EPS of $1.81 for the same period compares to -$1.32 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $6.84 billion, representing a surprise of -2.46%. The company delivered an EPS surprise of -0.55%, with the consensus EPS estimate being $1.82.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Oncology- Cell Therapy- Tecartus- U.S. $40 million versus $56.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -27.3% change.
• Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $166 million compared to the $238.12 million average estimate based on three analysts. The reported number represents a change of -33.1% year over year.
• Product Sales- Other- Other- U.S. $47 million compared to the $40.07 million average estimate based on three analysts. The reported number represents a change of -20.3% year over year.
• Product Sales- HIV- Genvoya- U.S. $305 million compared to the $299.29 million average estimate based on three analysts. The reported number represents a change of -8.1% year over year.
• Total product sales- Total: $6.61 billion versus $6.75 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.
• Revenues- Royalty contract and other revenues: $54 million compared to the $40.04 million average estimate based on six analysts. The reported number represents a change of +38.5% year over year.
• Product Sales- HIV- Genvoya- Total: $364 million versus the five-analyst average estimate of $375.96 million. The reported number represents a year-over-year change of -9.7%.
• Product Sales- HIV- Odefsey- Total: $281 million versus the five-analyst average estimate of $294.72 million. The reported number represents a year-over-year change of -9.4%.
• Product Sales- Total HIV- Total: $4.59 billion versus $4.56 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
• Product Sales- Veklury- Total: $302 million compared to the $387.03 million average estimate based on five analysts. The reported number represents a change of -45.6% year over year.
• Product Sales- Oncology- Cell Therapy- Tecartus- Total: $78 million versus $103.29 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -22% change.
• Product Sales- Oncology- Trodelvy- Total: $293 million compared to the $354.39 million average estimate based on five analysts. The reported number represents a change of -5.2% year over year.

View all Key Company Metrics for Gilead here>>>

Shares of Gilead have returned -2.6% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research